Abstract
Cancer Stem cells (CSC) are defined as a population of cells found within a tumor that have characteristics similar to normal stem cells. Like normal stem cells they have the potential to self renew and differentiate. The cellular origin of these cancer stem cells - whether they originate from stem cells that have lost the ability to regulate proliferation, or they arise from more differentiated population of progenitor cells that have acquired abilities to self-renew is still unclear. Investigators have reported isolation of cancer stem cells or tumor initiating cells using techniques developed for isolating hematopoietic stem cells and assays that identify a small subset of tumor initiating cells. The TICs are thought to play an important role in tumor development, progression as well response to therapy and relapse. Strategies that combine conventional therapies with newer approaches that target the TICs may be more effective in tumor cell kill are discussed.
Keywords: Cancer Stem cells (CSC), tumor, Hematopoietic cells, Drug Resistence, Inhibitors
Current Pharmaceutical Biotechnology
Title: Tumor Initiating Cells
Volume: 10 Issue: 2
Author(s): Nitu Bansal and Debabrata Banerjee
Affiliation:
Keywords: Cancer Stem cells (CSC), tumor, Hematopoietic cells, Drug Resistence, Inhibitors
Abstract: Cancer Stem cells (CSC) are defined as a population of cells found within a tumor that have characteristics similar to normal stem cells. Like normal stem cells they have the potential to self renew and differentiate. The cellular origin of these cancer stem cells - whether they originate from stem cells that have lost the ability to regulate proliferation, or they arise from more differentiated population of progenitor cells that have acquired abilities to self-renew is still unclear. Investigators have reported isolation of cancer stem cells or tumor initiating cells using techniques developed for isolating hematopoietic stem cells and assays that identify a small subset of tumor initiating cells. The TICs are thought to play an important role in tumor development, progression as well response to therapy and relapse. Strategies that combine conventional therapies with newer approaches that target the TICs may be more effective in tumor cell kill are discussed.
Export Options
About this article
Cite this article as:
Bansal Nitu and Banerjee Debabrata, Tumor Initiating Cells, Current Pharmaceutical Biotechnology 2009; 10 (2) . https://dx.doi.org/10.2174/138920109787315015
DOI https://dx.doi.org/10.2174/138920109787315015 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structural Features of the Interleukin-10 Family of Cytokines
Current Pharmaceutical Design Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety WISP1 (CCN4) Autoregulates its Expression and Nuclear Trafficking of β-Catenin during Oxidant Stress with Limited Effects upon Neuronal Autophagy
Current Neurovascular Research Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Editorial [Hot Topic: SOD Enzymes and Their Mimics in Cancer:Pro- vs Anti-Oxidative Mode of Action-Part II (Guest Editor: Ines Batinic-Haberle)]
Anti-Cancer Agents in Medicinal Chemistry Targeted Drug Delivery for Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design The Neuroprotective Effect of Ginkgo biloba Leaf Extract and its Possible Mechanism
Central Nervous System Agents in Medicinal Chemistry Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
Reviews on Recent Clinical Trials Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo
Current Pharmaceutical Design Diffuse Intrinsic Pontine Glioma (DIPG): Breakthrough and Clinical Perspective
Current Medicinal Chemistry Brain Tumor Detection from MR Images Employing Fuzzy Graph Cut Technique
Recent Advances in Computer Science and Communications Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design Exploiting Metabolic Differences in Glioma Therapy
Current Drug Discovery Technologies Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes
Current Medicinal Chemistry Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques
Combinatorial Chemistry & High Throughput Screening Genomic Expression in the Epileptogenic Hippocampus and Psychiatric Co-Morbidities
Current Psychiatry Reviews